- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
November 20, 2020Phil Sieff Selected as a Fellow of the Litigation Counsel of America
-
November 20, 2020Robins Kaplan Named Breastfeeding-Friendly Workplace
-
November 16, 2020David Martinez Elected to Robins Kaplan Executive Board
-
December 1-10, 20207th Annual IP Dealmakers Forum
-
December 11, 2020LGBTQ Legal Services: Transgender Name Change Clinic
-
December 17, 2020Valuation: The “Eye of the Beholder” Causes Disputes
-
November 2020Explaining the Almost Unexplainable
-
November 12, 2020If Your Company Received a Paycheck Protection Program Loan - The SBA Wants to Know How Necessary Was Your Loan
-
November 9, 2020Hatch-Waxman Venue Is Further Narrowed
-
November 25, 2020Financial Daily Dose 11.25.2020 | Top Story: Dow Jones Hits 30,000 Mark
-
November 24, 2020Financial Daily Dose 11.24.2020 | Top Story: Biden Taps Former Fed Chair Yellen as Treasury Pick
-
November 23, 2020Financial Daily Dose 11.23.2020 | Top Story: Pandemic and Global Economy Dominate Virtual G-20 Meeting
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents
October 1, 2018
A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.
Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says
All Content © 2018, Portfolio Media, Inc.
Related Publications
November 2020
Explaining the Almost Unexplainable
David Prange, Benjamen Linden, Vivek Biswas - Intellectual Property Magazine
October 2, 2020
Does an AB Rating Fill Out a Skinny Label?
Jeffrey Alan Hovden, Oren D. Langer
September 22, 2020
Herbal Patent Protection
Shui Li - 闻宁阁 American Intellectual Property
August 26, 2020
INSIGHT: Avoiding Trade Secret Claims After Seeing a Competitor’s Crown Jewels
Jake Holdreith, David Prange, Emily Tremblay - Bloomberg Law
August 3, 2020
Request for Amici: Tell SCOTUS to Incentivize Original Fictional Characters through Copyright
Patrick Arenz - IPWatchdog
Related News
September 15, 2020
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.